Edward H (National Institutes of Health, Bethesda, MD, USA) Kerns
Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, only a fraction have sufficient ADME (absorption, distribution, metabolism, elimination) properties, and acceptable toxicology properties, to become a drug product that will successfully complete human Phase I clinical trials. Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, Second Edition, provides scientists and students the background and tools to understand, discover, and develop optimal clinical candidates. This...
Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, only a fraction have suffic...
